A drug-repurposing screening identifies TgGSK3 as a novel drug-target for Apicomplexan parasites.
Ontology highlight
ABSTRACT: To shed light on the parasiticidal mechanisms of L2090314, we have adapted a workflow which combines a forward genetic approach based on transcriptome sequencing, computational mutation discovery, and CRISPR/Cas9 genome editing in Toxoplasma gondii. Drug-resistant parasites were generated by chemical random mutagenesis. Multiple independent resistant lines were isolated. Single nucleotide variations (SNVs) were identified based on NGS transcriptomic analysis. By focusing on mutations present in coding sequences, we identified a single gene, TgGSK3, that harbored SNVs leading to amino acid substitutions in the 8 drug-resistant lines obtained that were not present in the parental strain. Finally, using CRISPR/Cas9 genome editing we confirmed that the mutations identified confer resistance against LY2090314.
ORGANISM(S): Toxoplasma gondii
PROVIDER: GSE286338 | GEO | 2025/01/20
REPOSITORIES: GEO
ACCESS DATA